---
title: Empagliflozin after Acute Myocardial Infarction
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38587237/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240408180554&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Among patients at increased risk for heart failure after
  acute myocardial infarction, treatment with empagliflozin did not lead to a significantly
  lower risk of a first hospitalization for heart failure or death from any cause
  than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients at increased risk for heart failure after acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo. (Funded by Boehringer Ingelheim and Eli Lilly; EMPACT-MI ClinicalTrials.gov number, ...